Highly stable ruthenium complex for treating spinal cord injury and preparation method thereof
By developing a highly stable ruthenium complex Ru-EA, the problem of oxidative stress and inflammatory response in spinal cord injury is solved, and neuronal repair and functional recovery is achieved, providing a safe and effective drug solution.
Patent Information
- Application Number
- CN202411252619.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-09
AI Technical Summary
The prior art is difficult to effectively treat spinal cord injuries, especially in reducing oxidative stress and inflammatory responses and promoting neuronal repair, and lacks safe and stable small molecule drugs.
A highly stable ruthenium complex Ru-EA was developed. Through specific synthetic methods, it can promote neurite growth, repair hippocampal neuronal cells, and significantly improve the expression level and stability of ATOX1 protein, thereby resisting oxidative stress. Induced injury.
Ru-EA can effectively eliminate oxygen free radicals, reduce the ROS bioluminescence intensity in mice with spinal cord injury, promote spinal cord function recovery, significantly improve the expression and binding stability of ATOX1 protein, and provide a new drug idea for the treatment of spinal cord injury. No obvious toxicity to cells and tissues.
Smart Images

Figure CN118754915B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and particularly relates to a highly stable ruthenium complex for treating spinal cord injury and a preparation method thereof. Background Art
[0002] Spinal cord injury (SCI) is a common and serious neurological disease, mostly caused by traumatic injury. Once the spinal cord is damaged, control of higher nerve centers is lost, and sensory and motor functions below the injury site are completely or partially lost, leading to severe paralysis or death. Secondary injury of spinal cord injury is a multipathological process following primary injury, including a series of biochemical reactions, including oxidative stress, inflammatory response, and lipid peroxidation. This process produces a large amount of reactive oxygen species (ROS). The reactions triggered by these substances can destroy the subcellular structure of neurons and glial cells, leading to cell death. This may be the main reason for the poor prognosis of patients with spinal cord injury. Current research focuses on effectively removing ROS, reducing inflammation, and reducing neuronal death. Therefore, developing effective treatment strategies for secondary spinal cord injury may accelerate the recovery of patients.
[0003] Neutralization of excess ROS from inflammatory cells has been shown to significantly reduce secondary damage associated with acute spinal cord injury. The major antioxidant enzyme superoxide dismutase (SOD) catalyzes the conversion of superoxide anions into hydrogen peroxide and oxygen, thereby maintaining a balanced level of intracellular ROS. Catalase metabolizes H2O2 into oxygen and water. Antioxidant protein 1 (ATOX1) promotes the transfer of copper ions to copper-dependent antioxidant enzymes such as superoxide dismutase (SOD1). Activation of SOD1 by ATOX1 indirectly enhances the antioxidant defense of cells. In addition, since excess copper ions can generate harmful free radicals and induce oxidative stress, ATOX1 also protects cells by regulating intracellular copper ion levels. Heterocyclic structures and heteroatoms play a key role in active drug molecules, with more than 20% of small molecule drugs containing heteroatoms such as fluorine. Moreover, metalation of heterocyclic systems such as naphthyrimidine has recognized potential in treating a range of diseases, making it one of the main functionalization sites for future small molecule chemical drug development. Therefore, it is crucial to develop small molecule active compounds that target ATOX1 protein, have significant antioxidant effects, can be used to treat spinal cord injury, and have good safety. Summary of the invention
[0004] The purpose of the present invention is to solve the technical problems existing in the prior art, thereby providing a highly stable ruthenium complex Ru-EA for treating spinal cord injury, which can promote branch formation and neurite growth, repair hippocampal neuronal cells, resist damage induced by oxidative stress, quickly achieve functional recovery of mice with spinal cord injury, effectively reduce the ROS bioluminescence intensity in mice with spinal cord injury, have no obvious toxicity to cells or tissues, and have good safety; and it can significantly increase the expression level of ATOX1, and at the same time can stably bind to the ATOX1 protein, further improving its stability, providing new ideas for the treatment of spinal cord injury and subsequent drug development.
[0005] In order to solve the above technical problems, the present invention is implemented through the following technical solutions.
[0006] The first aspect of the present invention provides a highly stable ruthenium complex, the structural formula of which is shown below:
[0007] The highly stable ruthenium complex is named Ru-EA.
[0008] Preferably, the highly stable ruthenium complex is prepared by the following method:
[0009] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde, 2,6-diisopropylaniline and formic acid in organic solvent 1 and stir at room temperature overnight;
[0010] (2) removing the solvent by spin drying, followed by washing and drying to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder;
[0011] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 is dissolved in organic solvent 2 and stirred; then NH4PF6 is added and the reaction is continued with stirring;
[0012] (4) The solvent was removed under reduced pressure, and the obtained product was dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate was collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -2-phenylethanol-1-ol)Ru(N^N)Cl]PF6,Ru-EA).
[0013] Preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline in step (1) is 1:0.5-3; most preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline is 1:1.
[0014] Preferably, in step (1), the organic solvent 1 is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran and chloroform; most preferably, the organic solvent 1 is selected from methanol.
[0015] Preferably, the washing in step (2) is performed using water.
[0016] Preferably, the 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 has a molar ratio of 1:0.1-1; most preferably, 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 has a molar ratio of 1:0.5.
[0017] Preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 in step (3) is 1:1-3; most preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 is 1:2.
[0018] Preferably, in step (3), stirring is performed for 8-20 hours after adding the organic solvent 2.
[0019] Preferably, in step (3), stirring is performed for 3-12 hours after adding NH4PF6.
[0020] Preferably, the organic solvent 2 in step (3) is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran, and chloroform; most preferably, the organic solvent 2 is selected from methanol.
[0021] The second aspect of the present invention provides a method for preparing a highly stable ruthenium complex, comprising the following steps:
[0022] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde, 2,6-diisopropylaniline and formic acid in organic solvent 1 and stir at room temperature overnight;
[0023] (2) removing the solvent by spin drying, followed by washing and drying to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder;
[0024] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 is dissolved in organic solvent 2 and stirred; then NH4PF6 is added and the reaction is continued with stirring;
[0025] (4) The solvent was removed under reduced pressure, and the obtained product was dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate was collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -2-phenylethanol-1-ol)Ru(N^N)Cl]PF6,Ru-EA).
[0026] Preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline in step (1) is 1:0.5-3; most preferably, the molar ratio of 6-fluoroquinoline 2-carboxaldehyde to 2,6-diisopropylaniline is 1:1.
[0027] Preferably, in step (1), the organic solvent 1 is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran and chloroform; most preferably, the organic solvent 1 is selected from methanol.
[0028] Preferably, the washing in step (2) is performed using water.
[0029] Preferably, the 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 has a molar ratio of 1:0.1-1; most preferably, 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline and [(η 6 -2-phenylethanol-1-ol)RuCl2]2 has a molar ratio of 1:0.5.
[0030] Preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 in step (3) is 1:1-3; most preferably, the molar ratio of 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline to NH4PF6 is 1:2.
[0031] Preferably, in step (3), stirring is performed for 8-20 hours after adding the organic solvent 2.
[0032] Preferably, in step (3), stirring is performed for 3-12 hours after adding NH4PF6.
[0033] Preferably, the organic solvent 2 in step (3) is selected from one or more of methanol, ethanol, isopropanol, acetone, tetrahydrofuran, and chloroform; most preferably, the organic solvent 2 is selected from methanol.
[0034] The third aspect of the present invention provides a pharmaceutical composition for preventing and / or treating diseases associated with oxidative stress, comprising a highly stable ruthenium complex, the structural formula of which is as follows:
[0035] .
[0036] Preferably, the disease associated with oxidative stress is secondary spinal cord injury.
[0037] Preferably, the pharmaceutical composition optionally further comprises a pharmaceutically acceptable carrier.
[0038] Preferably, the pharmaceutically acceptable carrier is selected from one or more of a filler, a binder, a disintegrant, a lubricant, a preservative, a chelating agent, a flavoring agent, a colorant, a stabilizer, a solvent, and an antioxidant.
[0039] The fourth aspect of the present invention provides a use of a highly stable ruthenium complex in the preparation of a drug for preventing and / or treating diseases associated with oxidative stress, wherein the structural formula of the highly stable ruthenium complex is as follows:
[0040] .
[0041] Preferably, the disease associated with oxidative stress is secondary spinal cord injury.
[0042] The fifth aspect of the present invention provides a use of a highly stable ruthenium complex in the preparation of a drug for scavenging oxygen free radicals. The structural formula of the highly stable ruthenium complex is as follows:
[0043] .
[0044] Compared with the prior art, the present invention has the following technical effects:
[0045] The highly stable ruthenium complex Ru-EA provided by the present invention has excellent stability, can effectively scavenge oxygen free radicals, promote branch formation and neurite growth, repair hippocampal neuronal cells, and resist damage induced by oxidative stress, and has no obvious toxicity to cells or tissues, and has good safety. In vivo studies have shown that Ru-EA can significantly enhance the behavioral function of mice and reduce the oxidative stress response after spinal cord injury, thereby promoting the repair of spinal cord injury and improving the electrical signals and motor functions of mice with spinal cord injury. Further mechanism analysis found that Ru-EA can significantly increase the expression level of ATOX1, and can stably bind to the ATOX1 protein, further improving its stability. In general, the present invention provides a new research idea and drug source for drug treatment of spinal cord injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 Electronic absorption spectra of Ru-EA in different solvents.
[0047] Figure 2 is the fluorescence spectrum of Ru-EA at room temperature.
[0048] Figure 3 Schematic diagram of the hydrolysis stability results of Ru-EA.
[0049] Figure 4 Schematic diagram of the results of determining the free radical scavenging ability of Ru-EA using the ABTS method.
[0050] Figure 5 The DPPH method was used to determine the free radical scavenging ability of Ru-EA.
[0051] Figure 6 Schematic diagram of ROS analysis results in HT22 cells.
[0052] Figure 7 Schematic diagram of flow cytometry detection of Ru-EA reducing intracellular ROS levels.
[0053] Figure 8 Schematic diagram of the results of Ru-EA reducing intracellular ROS levels by scavenging superoxide anions.
[0054] Fig. 9 Schematic diagram of the effect of Ru-EA on neuronal cell survival rate.
[0055] Fig.10 This is a typical diagram of the protective effect of Ru-EA on neurons.
[0056] Fig.11 Schematic diagram of the effect of Ru-EA on the length and number of neuronal processes.
[0057] Fig.12 Schematic diagram of the effect of Ru-EA on ROS in SCI mice.
[0058] Fig.13 Schematic diagram of the effects of Ru-EA on Iba-1 and CD68 in SCI mice.
[0059] Fig.14 Schematic diagram of the effect of Ru-EA on iNOS in SCI mice.
[0060] Fig.15 These are typical images of hind limb recovery in each group of SCI mice 60 days after spinal cord injury.
[0061] Fig.16 Schematic diagram of BMS evaluation results for each group of SCI mice.
[0062] Fig.17 Schematic diagram of footprint experiment results.
[0063] Fig.18Schematic diagram of the inclined plate crawling experiment results.
[0064] Fig.19 This is a schematic diagram of the results of intercepting the hind limb movement trajectory of SCI mice during exercise.
[0065] Fig. 20 This is a schematic diagram of the curve of changes in joint angles during exercise in SCI mice.
[0066] Fig.21 Schematic diagram of the comparison of spinal cord status in each group of SCI mice.
[0067] Fig. 22 Schematic diagram of H&E analysis results of the spinal cord of SCI mice in each group.
[0068] Fig.23 Schematic diagram of the co-staining results of GFAP and NFH.
[0069] Fig.24 Schematic diagram of the effect of Ru-EA on motor evoked potentials in SCI mice.
[0070] Fig.25 Schematic diagram of the effect of Ru-EA on spinal cord signal recovery in SCI mice.
[0071] Fig.26 Schematic diagram of H&E staining analysis results of the main organs of SCI mice in each group.
[0072] Fig. 27 Schematic diagram of the effect of Ru-EA on ATOX1 expression level.
[0073] Fig.28 This is a schematic diagram of the fluctuation results of amino acids after Ru-EA binds to ATOX1 protein. DETAILED DESCRIPTION
[0074] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0075] Unless otherwise specified, the reagents used in the context of the present invention are all commercially available. The experimental animals used in animal experiments were purchased from the Experimental Animal Center of Southern Medical University, and the relevant procedures and methods were approved by the Animal Experiment Ethics Committee of Jinan University and followed its guidelines. The experimental methods used in the present invention are all conventional methods and techniques in the art.
[0076] Representative results from repeated biological experiments were presented in the context figures, and the data were presented as mean ± SD and mean ± SEM as specified in the figures. All experiments were repeated at least three times. The data were analyzed using GraphPad Prism 8.0 or SPSS 22.0 software. Conventional medical statistical methods such as t-test, chi-square test, and analysis of variance were used to compare the mean differences between two or more groups. p A value < 0.05 was considered a significant difference.
[0077] Example 1 Preparation and characterization of highly stable ruthenium complexes
[0078] A highly stable ruthenium complex Ru-EA, the preparation method of which comprises the following steps:
[0079] (1) Dissolve 6-fluoroquinoline 2-carboxaldehyde (5 mmol, 0.875 g), 2,6-diisopropylaniline (5 mmol, 0.885 g), and formic acid (100 μL) in methanol (5 mL) and stir at room temperature overnight.
[0080] (2) The solvent was removed by evaporation to dryness on a rotary evaporator, and the obtained product was washed with 5 mL of water and dried at room temperature to obtain 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (N^N) in the form of a yellow powder; its NMR identification data are as follows: 1 HNMR (500MHz, CDCl3) δ8.51–8.41 (m, 2H), 8.29–8.18 (m, 2H), 7.54 (dt, J =11.6, 5.7Hz, 2H), 7.22–7.11 (m, 3H), 2.99 (dt, J =13.7, 6.9Hz, 2H), 1.28 (d, J =6.8Hz, 1H), 1.19(d, J =6.9Hz, 11H).
[0081] (3) 2,6-diisopropyl-N-(6-fluoroquinolin-2-ylmethylene)aniline (0.10 mmol) and [(η 6 -2-phenylethanol-1-ol)(bz-EA)RuCl2]2 (0.05 mmol) was dissolved in methanol (20 mL) and stirred for 12 h in a dry round-bottom flask equipped with a stirrer and a nitrogen atmosphere; then NH4PF6 (0.2 mmol) was added and the reaction was stirred for 6 h.
[0082] (4) After complete conversion, the solvent is removed under reduced pressure, and the obtained product is dissolved in dichloromethane and filtered using a diatomaceous earth filter funnel. The filtrate is collected and added with n-hexane for slow diffusion and recrystallization to obtain ([(η 6 -2-phenylethanol-1-ol)Ru(N^N)Cl]PF6,Ru-EA); its NMR identification data are as follows: 1 HNMR (500MHz, DMSO) δ9.25 (s, 1H), 8.93 (d, J =8.3Hz, 1H), 8.80 (dd, J =9.7, 4.9Hz, 1H), 8.38 (d, J =8.3Hz, 1H), 8.24–8.19 (m, 1H), 8.10–8.05 (m, 1H), 7.57 (dd, J =7.0, 3.9Hz, 2H), 7.48 (dd, J =6.0, 3.2Hz, 1H), 6.47–6.38 (m, 2H), 5.78–5.76 (m, 1H), 5.36 (t, J =5.8Hz, 1H), 5.29(d, J =6.0Hz, 1H), 4.89(t, J =5.0Hz, 1H), 3.84–3.78 (m, 1H), 3.72 (dd, J =11.4, 5.7Hz, 2H), 2.78 (dd, J =11.8, 6.3Hz, 1H), 2.69–2.58 (m, 2H), 1.40 (d, J =6.7Hz, 3H), 1.28 (dd, J =27.5, 6.7Hz, 6H), 0.87 (d, J =6.7Hz, 3H).Anal.Calcd.For[(η 6 -bz-EA)Ru(L1)Cl]PF6(738.10): C, 48.82; H, 4.51; N, 3.80; Found: C, 48.80; H, 4.54; N, 3.82.MS: m / z559.16.[(η 6 -bz-EA)Ru(L1)+H] + .
[0083] The Ru-EA complex was isolated as hexafluorophosphate (PF6-) salt. Its room temperature (298K) electronic absorption spectra in solvents such as water, methanol, dimethyl sulfoxide and acetonitrile are shown in Figure 2. Figure 1As shown. The significant absorption band below 300nm is attributed to the spin-allowed ligand-centered π-π* transition. The featureless band in the range of 300-360nm is caused by the π-π* ligand-centered charge transfer (LCCT) from phenyl to pyridine and the metal-to-ligand charge transfer (MLCT) transition, represented by the dπ(Ru) to π*(phenyl) transition. The bands in the visible spectrum (above 360nm) correspond to singlet and triplet MLCT transitions. The absorption spectrum of Ru-EA has slight changes in solvents of different polarities. The fluorescence spectrum of Ru-EA at room temperature is shown as Figure 2 As shown, the results show that when excited at 405nm, it emits fluorescence with a peak wavelength around 550nm and a significant fluorescence intensity.
[0084] For transition metal-based complexes, hydrolysis of the M-Cl bond is usually an essential activation step. The hydrolytic stability of the Ru-EA complex in DMSO / H2O solution (2:8 ratio) was monitored by UV-Vis spectroscopy and it was found that Ru-EA has excellent stability (see Figure 3 ).
[0085] Example 2 Study on the scavenging ability of oxygen free radicals
[0086] The free radical scavenging ability of Ru-EA was determined by ABTS method and DPPH method, as follows:
[0087] (1) The ABTS stock solution (5 mmol / L, dissolved in PBS) was reacted with the manganese oxide solution to form ABTS free radicals (ABTS•+).
[0088] (2) Mixing different concentrations of Ru-EA with the ABTS radical solution prepared in step (1).
[0089] (3) The absorbance at 734 nm was measured for 120 min using a cellular imaging multimode reader (Cytation 5, BioTek Instruments Inc.).
[0090] The results showed that with the increase of Ru-EA concentration and the extension of time, the absorbance of the solution gradually decreased, indicating that Ru-EA has significant antioxidant capacity (see Figure 4 )(*** p <0.001).
[0091] Subsequently, the same method was used to conduct an in vitro free radical scavenging test of DPPH (1,1-diphenyl-2-picrylhydrazyl), and the results were the same as those of the ABTS experiment (see Figure 5 )(*** p <0.001).
[0092] To determine whether Ru-EA can scavenge ROS in cells and achieve antioxidant effects, in vitro studies were performed using the HT22 mouse hippocampal neuronal cell line. HT22 is highly sensitive to glutamate and is an effective model for in vitro oxidative stress studies. Under glutamate-induced damage, HT22 cells can produce a large amount of ROS. Therefore, HT22 cells were cultured in complete medium containing glutamate to induce damage and simulate the desired oxidative stress state. Subsequently, cells in an oxidative stress state were treated with Ru-EA. Finally, the antioxidant effect of Ru-EA in the HT22 cell line was evaluated by detecting various reactive oxygen species levels.
[0093] In order to determine the optimal working concentration of Ru-EA, the complete culture medium containing different concentrations of Ru-EA was prepared by the half-volume dilution method, and the toxicity of different concentrations of drugs on HT22 cells was detected by the CCK-8 kit. According to the experimental results, the highest working concentration of Ru-EA was determined to be 250 μM for subsequent experiments. Next, the DCFH-DA and DHE kits were used to detect the intracellular ROS level of HT22 cells to observe the antioxidant effect of Ru-EA. The DCFH-DA kit uses the fluorescent probe DCFH-DA to detect the total ROS level. DCFH-DA enters the cell through the cell membrane and is hydrolyzed by esterase to generate DCFH. DCFH cannot penetrate the cell membrane and is therefore retained in the cell. Then, intracellular ROS converts non-fluorescent DCFH into DCF, which emits fluorescence. Therefore, the fluorescence level of intracellular DCF reflects the total intracellular ROS level. The results showed that after glutamate treatment of HT22 cells, the intracellular fluorescence intensity increased significantly, indicating that HT22 cells were in a state of strong oxidative stress. Compared with the pure glutamate injury group, the fluorescence intensity of cells treated with different concentrations of Ru-EA was significantly decreased (see Figure 6 ) (Ctrl (Control) is the blank control group, Inj (Injury) is the injury group, the same below; *** p <0.001), which shows that Ru-EA can reduce the level of intracellular ROS and has a significant antioxidant effect.
[0094] In order to improve the credibility of the experimental results, flow cytometry was also used to detect the ability of drugs to reduce intracellular ROS levels. The results were consistent with the above, that is, Ru-EA can significantly reduce the intracellular ROS level of HT22 cells (see Figure 7 )(*** p <0.001).
[0095] Since superoxide anions are the precursors of many intracellular ROS, detecting their levels can better reflect intracellular oxidative stress. DHE is a widely used superoxide anion fluorescence detector that can be taken up by living cells and react with intracellular superoxide anions to produce products such as ethidium bromide. These products bind to RNA or DNA and produce fluorescence. The higher the level of intracellular superoxide anions, the more ethidium bromide is produced and the stronger the fluorescence. Similar to the DCFH-DA probe experiment, after treating HT22 cells in an oxidative stress state with different concentrations of Ru-EA, the intracellular fluorescence intensity was significantly reduced compared with the untreated group. This shows that Ru-EA can effectively scavenge superoxide anions and significantly reduce intracellular ROS levels (see Figure 8 ). In summary, Ru-EA can reduce the level of ROS in HT22 cells and achieve significant antioxidant effect.
[0096] Example 3 Study on the repair effect on neurons
[0097] The above studies show that Ru-EA has a significant antioxidant effect. Since neurons are sensitive to peroxidative environments and have low tolerance and susceptibility to oxidative stress and damage, Ru-EA has potential application prospects in the field of neuroprotection. In order to explore whether it can relieve oxidative stress by removing ROS, thereby protecting neurons and promoting the repair of neurons after injury, subsequent experiments were carried out by extracting primary neurons.
[0098] First, the toxicity of Ru-EA to neuronal cells was studied. The specific steps are as follows:
[0099] (1) The hippocampal tissue of 1-day-old Sprague-Dawley (SD) rats was minced with ophthalmic scissors and added to a 15 mL centrifuge tube (Corning). Papain (Sigma, Cat#P4762) was added and digested at 37°C for 25 min.
[0100] (2) Use bovine serum albumin to terminate the action of protease and then wash the tissue.
[0101] (3) The isolated hippocampal neurons were seeded at a concentration of 20,000 cells / mL in a 96-well plate (Corning), with 200 μL per well, and cultured in DMEM medium (with glutamine, Gibco, Carlsbad, CA, Cat#12430054) containing 10% fetal bovine serum and 10% nutrient mixture F-12 in a 37°C, 95% O2, 5% CO2 incubator for 6 h.
[0102] (4) Replace the original culture medium with Neurobasal medium containing 5% B-27 (Gibco) and culture in an incubator at 37°C, 95% O2, and 5% CO2 for 24 h.
[0103] (5) After cell adhesion, different concentrations (3.9, 7.8, 15.6, 31.3, 62.5, unit: μmol / L) of Ru-EA were added to each well and incubated for another 24 h.
[0104] (6) CCK8 kit (Beyotime, Cat#C0038) was used to assess the viability of cultured hippocampal neurons.
[0105] The results are as follows Fig. 9 The results showed that at each concentration of 3.9-62.5μmol / L studied, the survival rate of hippocampal neuron cells after Ru-EA treatment exceeded 100%, and there was no significant difference in survival rate compared with the blank control group ( p >0.05), Ru-EA fluorescence was absorbed by neurons and accumulated in the cytoplasm and processes of neurons, which clearly showed that it had excellent safety and had no obvious cytotoxicity to hippocampal neurons.
[0106] Subsequently, different concentrations of Ru-EA were used to treat the damaged neurons to observe its protective effect on the neurons. The specific steps are as follows:
[0107] (1) The hippocampal tissue of 1-day-old Sprague-Dawley (SD) rats was minced with ophthalmic scissors and added to a 15 mL centrifuge tube (Corning). Papain (Sigma, Cat# P4762) was added and digested at 37°C for 25 min.
[0108] (2) Use bovine serum albumin to terminate the action of protease and then wash the tissue.
[0109] (3) The isolated hippocampal neurons were seeded at a concentration of 20,000 cells / mL in a 24-well plate (Corning), with 500 μL per well, and cultured in a 37°C, 95% O2, 5% CO2 incubator for 24 h using DMEM medium (containing glutamine, Gibco, Carlsbad, CA, Cat#12430054) containing 10% fetal bovine serum and 10% nutrient mixture F-12.
[0110] (4) The original culture medium was replaced with a culture medium containing 120 μM glutamate and the cells were cultured in an incubator at 37°C, 95% O2, and 5% CO2 for 12 h to form a hippocampal neuron injury model.
[0111] (5) Different concentrations of Ru-EA (15.6, 31.3, 62.5, unit: μmol / L) were added to observe its effects on neurons. The Control group was a blank control group in which the hippocampal neurons were not damaged.
[0112] The results are as follows Figure 10-11 As shown, the effect of Ru-EA on neurite growth was evaluated by quantifying the length and total number of branched neurites. The results showed that the length and number of neurites in glutamate-injured neurons were significantly reduced, while Ru-EA was able to promote neurite formation and neuronal neurite growth compared with glutamate-injured neurons, and this promotion was positively correlated with its concentration within a certain range. In summary, it can be clearly seen that Ru-EA treatment can significantly promote neurite formation and neuronal neurite growth, indicating that Ru-EA can repair hippocampal neuronal cells and resist damage induced by oxidative stress (*** p <0.001).
[0113] Example 4 In vivo functional study
[0114] In order to explore whether Ru-EA can reduce oxidative stress and inhibit neuroinflammation in vivo, thereby protecting neurons and promoting the recovery of injured spinal cord, a mouse spinal cord injury model was established to observe the levels of oxidative stress and inflammation. The specific steps are as follows:
[0115] (1) Twenty-four 6-week-old female mice were selected and divided into four groups, with 6 mice in each group, including a blank control group (Control group, 6 mice), a sham control group (sham group, only the lamina was removed without damaging the spinal cord, 6 mice), a model group (Injury group, 6 mice), and a Ru-EA group (Injury+Ru-EA group, 6 mice) (Ru-EA 200 µL, concentration of 312.5 μM, was injected intravenously starting from the second day after spinal cord injury, once a day for 7 consecutive days). The method for constructing a mouse model of spinal cord injury is as follows:
[0116] a. Remove the hair on the back of the mouse to expose the skin on the back of the mouse;
[0117] b. Anesthesia: 1.25% tribromoethanol was injected intraperitoneally at a dose of 200 μg / 20 g. Stable breathing, significantly weakened limb muscle strength, and disappearance of pain reflex and corneal reflex indicated successful anesthesia.
[0118] c. Expose the spinal cord: wipe the skin twice with iodine cotton balls to disinfect it; determine the level of the 9th to 11th thoracic vertebrae (T9-T11), and make a 2.5 cm long longitudinal incision in the middle of the back at the T9-T11 level. Bluntly dissect the paraspinal muscles, remove the spinous processes and lamina with bone-cutting forceps, completely expose the T9-T11 segment spinal cord, use a fixator to fix the T10 plane, and remove the T10 lamina. Be careful to avoid additional tissue damage during the operation. Then use a fixator to open and fix it to fully expose the spinal cord;
[0119] d. Fix the mouse to the Louisville Injury System Apparatus (LISA), adjust the spinal cord under the impactor, and simultaneously use the monitoring laser beam to confirm the impact position, and determine the degree of spinal cord injury by the impact depth. In this embodiment, the collision tip is set to 18 psi, the impact depth is 1.0 mm, and the injury time is 0.5 s; after the collision is completed, remove the mouse from the injury device and remove it from the fixator. After sufficient hemostasis, use sutures to suture the mouse muscles and skin. Mice in the sham operation group underwent T10 laminectomy without spinal cord collision;
[0120] e. Close the incision and inject gentamicin 2000U subcutaneously once a day for 3 consecutive days. Perform artificial bladder emptying every 8 hours until spontaneous urination occurs.
[0121] (2) Small animal in vivo imaging: In vivo imaging of mice was performed on the third day after injury. First, 0.1 mL / 20 g of L-012 (chemiluminescent (CHL) probe) was intraperitoneally injected, and the concentration of L-012 was 4 mg / ml. Five minutes later, 1.25% tribromoethanol was injected intraperitoneally at a dose of 200 µg / 20 g for anesthesia. After successful anesthesia, small animal in vivo imaging was performed.
[0122] The results are as follows Fig.12 The results showed that ROS bioluminescence was rarely seen in the spinal cord of normal mice, while the bioluminescence intensity of ROS in the spinal cord of mice with spinal cord injury was significantly increased and increased over time. After Ru-EA treatment, the bioluminescence intensity of ROS was significantly reduced (*** p <0.001), further confirming that Ru-EA has significant oxygen free radical scavenging and spinal cord injury repair effects in vivo.
[0123] Iba-1 is highly expressed in microglia and is involved in inflammatory responses. During nerve injury, microglia proliferate, migrate, and activate by expressing Iba-1, thereby promoting inflammatory responses. CD68 is a glycoprotein that is mainly expressed on the surface of monocytes, macrophages, and other cells. During inflammatory responses, CD68-positive monocytes and macrophages migrate to the site of inflammation. Therefore, changes in CD68 expression levels can reflect the activation state of these cells and the extent to which they participate in inflammatory responses. Spinal cord tissues of mice were obtained on the third day after spinal cord injury, and the tissues were labeled with Iba-1 and CD68 for immunofluorescence staining to assess the level of neuroinflammation. The results are shown in Figure 2. Fig.13 As shown, there were a large number of Iba-1 and CD68 positive cells in the injured area of the spinal cord tissue of mice in the injury group, indicating a strong inflammatory response. In contrast, the number of Iba-1 and CD68 positive cells in the Ru-EA treatment group was significantly reduced, indicating that Ru-EA treatment can alleviate neuroinflammation at an early stage.
[0124] iNOS is an enzyme induced by cells in response to specific stimuli. During inflammation, overexpression of iNOS and overproduction of NO can lead to tissue damage and increased inflammation. Therefore, in order to improve the credibility of the results, iNOS was labeled and immunofluorescence staining and observation were performed. The results showed that, consistent with previous research results, iNOS was significantly reduced in the spinal cord injury site of mice treated with Ru-EA, suggesting that it alleviated neuroinflammation (see Fig.14 ).
[0125] Since Ru-EA can effectively relieve oxidative stress and inhibit neuroinflammation in mice, behavioral experiments were performed to explore whether it can promote the recovery of lower limb motor function in mice with spinal cord injury. The BMS score can be used to evaluate changes in the motor function of the hind limbs of mice with spinal cord injury, and is a reliable indicator of hind limb ankle activity, coordination, and claw posture. Specifically, after the SCI model was constructed, the lower limb movements of each group of mice were timed every three days and scored using the BMS scoring method. The results are shown in Figures 15-16. The results showed that the motor function of the control group and the sham operation group was not restricted, with a continuous BMS score of 9, while the BMS scores of the injury group and the drug treatment group dropped to 0 after successful modeling. Over time, the scores gradually increased, and the difference in scores between the injury group and the Ru-EA group began to be statistically significant on the 15th day (*** p <0.001). In summary, Ru-EA treatment can significantly promote the recovery of motor function of both lower limbs in mice with spinal cord injury.
[0126] Then, a footprint experiment was conducted to analyze the movement of the mouse's lower limbs. Each group of mice was allowed to crawl freely on a clean paper and their footprints were recorded. The results showed that the gait of the mice in the control group and the sham operation group was normal, the mice in the injury group had a dragging phenomenon, and the gait of the mice in the drug treatment group was restored to a certain extent compared with the injury group (see Fig.17 )(** p <0.01,*** p <0.001). Similar results were obtained in the inclined board crawling test (see Fig.18 ).
[0127] Deep Lab Cut is an efficient 3D markerless pose estimation method based on deep neural network transfer learning. It can achieve excellent results with very little training data and can be used to draw the shape and trajectory of the hind limbs of mice when they move. Figure 19-20 The following are typical images of the key frames of the hind limb motion trajectory of each group of mice during the exercise process. The results showed that the knee and ankle joints of the hind limbs of the mice in the injury group were stiff and dragged continuously. The joints of the mice in the Ru-EA group showed a significant increase in mobility and showed a large-stride walking posture, indicating that the Ru-EA group had an excellent effect on the recovery of hind limb motor function (see Fig.19 ). Fig. 20The following are the curves of the change of angles of each joint during the movement of each group of mice, and the average height and average speed of each joint of the mice were statistically analyzed. The results showed that the height of each joint in the Ru-EA treatment group was higher than that in the simple injury group, indicating that the mice in this group no longer crawled in a dragging posture after treatment, but showed a certain degree of normal gait.
[0128] Example 5 Effect on Spinal Cord Injury
[0129] Mouse spinal cord tissue was taken for pathological study to explore the effect of drug treatment after spinal cord injury. First, the spinal cord was removed for visual inspection. The spinal cord of the injury group showed obvious cavities, while the spinal cord of the Ru-EA treatment group had significantly fewer cavities and good integrity (see Fig.21 H&E staining showed that the continuity of the spinal cord tissue in the injury group was poor, while the Ru-EA treatment group had a significant effect on the restoration of spinal cord tissue continuity (see Fig. 22 ).
[0130] In order to further study the protective and repair effects of the drug on spinal cord tissue, specific neural markers were used for immunohistochemical analysis. Glial fibrillary acid protein (GFAP) is mainly distributed in astrocytes in the central nervous system and is used to mark astrocytes and glial scar formation. Neurofilament protein-H (NFH) is an intermediate filament in the cytoplasm of neurons and is used to mark neurons in spinal cord tissue. The status of neurons and glial scars after spinal cord injury was observed by co-staining of GFAP and NFH. The results showed that compared with the injury group, the density of spinal cord glial scars in Ru-EA-treated mice was significantly reduced, and the number of surviving neuronal cells was significantly increased, suggesting that Ru-EA may inhibit the formation of glial scars and increase neuronal survival (see Fig.23 ).
[0131] After spinal cord injury, a large number of neurons with signaling functions at the site of injury are broken and die, resulting in weakened signals. Neurophysiological tests will show a decrease in the amplitude of motor evoked potentials (MEPs) and electrical conduction signals in the spinal cord. Therefore, electrophysiological tests were used to evaluate the neurological recovery of the spinal cord in mice with spinal cord injury. Specifically, electrodes were used to stimulate the cerebral cortex, receive electrical signals from the contralateral calf gastrocnemius muscle, and record motor evoked potentials. Electrodes were used to stimulate the spinal cord at the proximal end of the spinal cord injury, and electrical signals were received at the proximal end of the spinal cord injury, 2 mm distal to the injury, and 5 mm distal to the injury.
[0132] The results showed that the MEP amplitude of mice after spinal cord injury was lower than that of the control group, indicating that the corticospinal tract was significantly damaged. However, after Ru-EA treatment, the motor evoked potential was significantly restored. This indicates that Ru-EA treatment can increase the number of neurons with electrical conduction function in the anterior horn of the spinal cord (see Fig.24 )(*** p <0.001). In addition, when the spinal cord tissue proximal to the spinal cord injury site was stimulated, the amplitude of the electrical signal above the injured segment did not change significantly. The amplitude of the electrical signal received 2mm distal to the spinal cord injury site was lower than that of the control group, indicating that neuronal damage was obvious. However, after Ru-EA treatment, its amplitude increased significantly, indicating that Ru-EA promoted the recovery of neurons; the amplitude of the electrical signal 5mm distal to the spinal cord injury site also showed a similar trend (see Fig.25 )(*** p <0.001). The above electrophysiological results show that Ru-EA treatment can promote the recovery of spinal cord signals in mice with spinal cord injury.
[0133] To further investigate whether the drug is toxic to the organs of mice, sections of the organs of mice were taken on the 60th day of the experiment and observed by H&E staining. Fig.26 As shown, no pathological changes were observed in the organs, indicating that Ru-EA was biocompatible in mice, showed no obvious toxicity, and had good safety.
[0134] Example 6 Study on mechanism of action and binding stability
[0135] By using liquid chromatography-mass spectrometry (LC-MS) combined with proteomics to analyze the changes in proteins in the spinal cord of each group of SCI mice, it was found that ATOX1 protein was significantly upregulated after Ru-EA treatment. ATOX1 protein is a highly conserved water-soluble protein that was first identified as a metal homeostasis factor in Saccharomyces cerevisiae. The protein consists of two short α helices and four antiparallel β helices that undergo a classical iron redox fold. ATOX1 protein can transfer copper ions to copper-dependent antioxidant enzymes such as superoxide dismutase (SOD1). Therefore, by activating SOD1, ATOX1 protein can indirectly enhance the antioxidant capacity of cells. In addition, since excessive copper ions in cells can produce harmful free radicals and cause oxidative stress, ATOX1 protein can also protect cells from oxidative stress by regulating the balance of copper ions.
[0136] To verify the above findings, proteins were extracted from primary neurons for Western Blot experiments to determine whether Ru-EA upregulated the expression of ATOX1 protein. The results showed that the expression of ATOX1 protein was decreased in the injury group compared with the control group, while the expression in the Ru-EA treatment group was increased (see Fig. 27 )(*** p<0.001), which shows that Ru-EA can indeed upregulate the expression of ATOX1 protein. At the same time, the immunohistochemical fluorescence experiment was performed on the spinal cord tissue sections of mice to observe the changes of ATOX1 protein in each group of mice. The results were similar, that is, Ru-EA can significantly upregulate the expression of ATOX1 protein. In summary, the main protein target of Ru-EA may be ATOX1 protein.
[0137] Molecular docking and dynamic simulation experiments were then carried out, and the results showed that Ru-EA was tightly bound to the ATOX1 protein. After binding to the ATOX1 protein, the RMSD of Ru-EA was about 2Å, and the binding site remained stable. The radius of rotation (Rg) is used to measure the compactness of atoms in the system to respond to the stability of small molecule binding to proteins, providing additional analysis of the influence of atomic compactness. The analysis found that the average Rg value of atoms in the Ru-EA binding system was 10.92Å. The solvent accessible surface area (SASA) of the protein-small molecule complex reflects the size of the solvent exposed area of the protein-small molecule binding system, which corresponds to the binding stability. The larger the SASA, the more protein-small molecule complexes are exposed to the solvent, indicating reduced stability. The smaller the SASA, the better the structural stability and the larger the embedded area. The analysis found that the average SASA in the Ru-EA system was 30948.28Å. 2 , indicating that the Ru-EA binding complex has good stability. The root mean square fluctuation (RMSF) measures the freedom of motion of atoms and represents the flexibility of the molecular structure. It determines the degree of change of each atom relative to its average position. When the protein is stably bound to the small molecule, the RMSF value is relatively stable and fluctuates less, while when the protein is unstably bound to the small molecule, the RMSF fluctuates more. Fig.28 The results showed that the RMSF of the protein after Ru-EA binding was small, which further demonstrated that Ru-EA had excellent binding stability. The above results clearly showed that Ru-EA could stably bind to ATOX1 protein.
[0138] In summary, the highly stable Ru-EA provided by the present invention can effectively scavenge oxygen free radicals. After being treated with Ru-EA, branch formation and neurite growth can be promoted, indicating that Ru-EA can repair hippocampal neuronal cells and resist damage induced by oxidative stress. In addition, in vivo studies have shown that Ru-EA can quickly achieve functional recovery in mice with spinal cord injury, and the improvement level of BMS score is significantly improved compared with the injury group; at the same time, Ru-EA can significantly enhance the behavioral function of mice. In addition, Ru-EA can effectively reduce the bioluminescence intensity of ROS in mice with spinal cord injury, further confirming that Ru-EA has significant oxygen free radical scavenging and spinal cord injury repair effects in vivo. And Ru-EA has no obvious toxicity to cells or tissues, and has good safety. In-depth mechanism analysis found that Ru-EA can significantly increase the expression level of ATOX1, and at the same time can stably bind to ATOX1 protein, further improving its stability. In general, the present invention provides a new research idea and drug source for drug-assisted treatment of spinal cord injury.
[0139] The above specific implementation method part specifically introduces the analytical method involved in the present invention. It should be noted that the above introduction is only to help those skilled in the art better understand the method and ideas of the present invention, rather than limiting the relevant content. Without departing from the principle of the present invention, those skilled in the art may also make appropriate adjustments or modifications to the present invention, and the above adjustments and modifications shall also fall within the scope of protection of the present invention.
Claims
1. Use of a highly stable ruthenium complex in the preparation of a medicament for preventing and / or treating diseases associated with oxidative stress, characterized in that: The structural formula of the highly stable ruthenium complex is shown below: 。 2. The use according to claim 1, characterized in that: The disease associated with oxidative stress is secondary spinal cord injury.
3. Use of a highly stable ruthenium complex in the preparation of a drug for scavenging oxygen free radicals, characterized in that: The structural formula of the highly stable ruthenium complex is shown below: 。
